Core Insights - Liquidia Corporation reported a second-quarter loss of 49 cents, which was worse than the consensus estimate of a loss of 43 cents, but sales reached $8.84 million, significantly exceeding the consensus of $3.86 million [1][2] Financial Performance - The company experienced a second-quarter loss of 49 cents per share, missing the expected loss of 43 cents [1] - Sales for the quarter were reported at $8.84 million, surpassing the consensus estimate of $3.86 million [1] Product Development and Market Response - Liquidia analyzed interim data from the ASCENT study, which involved 54 patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The FDA approved and launched YUTREPIA™ (treprostinil) inhalation powder, with over 350 physicians prescribing it within 11 weeks of approval, leading to more than 900 unique patient prescriptions and over 550 patient starts [3] Analyst Ratings and Price Targets - Wells Fargo analyst Tiago Fauth maintained an Overweight rating on Liquidia and raised the price target from $25 to $31 [6] - Raymond James analyst Ryan Deschner maintained a Strong Buy rating and increased the price target from $33 to $41 [6]